BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

BeiGene Ltd.

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ONC) investors are watching a new update on a BeiGene ...

BeOne Medicines (ONC) Investors Track New Data from BeiGene’s Chronic Urticaria Trial

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. The Phase 1a/1b study, officially titled “Phase 1a/1b Randomized Study ...

BeOne Medicines’ BGB-45035 Trial Completion: What Early Skin Data Could Mean for ONC Investors

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oncolytics Biotech (ONCY), Stryker (SYK) and Alker...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (ONCY), Stryker (SYK) and Alkermes (ALKS)

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ONC) is running a Phase 1 study called “An Open-Label,...

BeOne Medicines Advances BGB-58067 With Key Drug-Interaction Study in Healthy Volunteers

The latest announcement is out from Oncolytics Biotech ( ($ONCY) ). On June 16, 2026, Oncolytics Biotech Inc. announced that the U.S. Patent and Tr...

Oncolytics Biotech Secures New Pelareorep Manufacturing Patent

In a report released today, Etzer Darout from Barclays maintained a Buy rating on BeOne Medicines, with a price target of $409.00. According to Tip...

BeOne Medicines (ONC) Gets a Buy from Barclays

Oncopeptides AB ( ($SE:ONCO) ) has shared an announcement. Oncopeptides has submitted a Type II variation application to the European Medicines Age...

Oncopeptides seeks EMA approval to move Pepaxti into earlier-line multiple myeloma treatment

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY). Enlive...

Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY)

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines has completed a Phase 1a/1b study called “A Phase 1a/1b...

BeOne Medicines Advances CDK4 Cancer Drug With Completion of Key Phase 1 Trial

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines has completed a first-in-human Phase 1 study of BGB-C35...

BeOne Medicines Completes First-in-Human Study of New B7H3 Cancer Drug

Oncopeptides AB ( ($SE:ONCO) ) has shared an announcement. Oncopeptides has enrolled the first patient in its MARINA real-world evidence study in G...

Oncopeptides launches German real-world study to bolster Pepaxti’s myeloma profile

In a report released on June 3, from CICC maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$250.00. Currently, the analyst ...

BeOne Medicines Ltd (6160) Gets a Buy from CICC

Citi analyst maintained a Buy rating on BeOne Medicines Ltd on June 2 and set a price target of HK$271.80. The company’s shares closed yesterday at...

Citi Keeps Their Buy Rating on BeOne Medicines Ltd (6160)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines ...

Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines (ONC)

In a report released today, Kalpit Patel from Wolfe Research maintained a Buy rating on BeOne Medicines, with a price target of $340.00. Patel cove...

Wolfe Research Sticks to Its Buy Rating for BeOne Medicines (ONC)

In a report released today, Etzer Darout from Barclays maintained a Buy rating on BeOne Medicines, with a price target of $409.00. Darout covers th...

Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)

In a report released today, Yaron Werber from TD Cowen reiterated a Buy rating on BeOne Medicines, with a price target of $424.00. Werber covers th...

TD Cowen Remains a Buy on BeOne Medicines (ONC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioline RX Ltd Sponsored ADR (BLRX), BeOne Medicines...

Analysts Offer Insights on Healthcare Companies: Bioline RX Ltd Sponsored ADR (BLRX), BeOne Medicines (ONC) and Autonomix Medical, Inc. (AMIX)

Oncolytics Biotech ( ($ONCY) ) just unveiled an announcement. On June 1, 2026, Oncolytics Biotech Inc. reported initial preclinical data showing th...

Oncolytics Highlights Pelareorep-RAS Combo Preclinical Cancer Results

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. The phase 2 study “A Phase 2, Randomized, Active-Controlled, Open-Label...

New Combo Trial in Esophageal Cancer: What LBL-007’s Phase 2 Update Means for ONC Investors

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines has launched a first-in-human study called “A Multicent...

BeOne Medicines Advances First-in-Human Solid Tumor Trial With BG-C0979

Oncopeptides AB ( ($SE:ONCO) ) has provided an update. Oncopeptides AB will showcase an extensive data package on its peptide-drug conjugate melflu...

Oncopeptides to spotlight Pepaxti data and PDC strategy at EHA 2026

The latest update is out from Oncopeptides AB ( ($SE:ONCO) ). Oncopeptides AB has signed an exclusive agreement with Salus Group affiliate SALUS Ve...

Oncopeptides Accelerates CEE Expansion for Pepaxti via Exclusive Salus Distribution Deal

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. The Phase 3 study “An Open-Label, Randomized, Multicenter Phase 3 Study...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ONC	$270.15	+2.84%	367.88K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ONC	$270.15	+2.8%	367.88K
3
4
5
6

ONC

ONC

No Data Available

Get BeiGene Ltd. Data in Excel

Get BeiGene Ltd. Data in Excel